AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. (December 2016)

• Record Type: Journal Article
• Authors: Lillian, S.; De Bono, J.; Higano, C.; Shapiro, G.; Brugger, W.; Mitchell, P.; Colebrook, S.; Klinowska, T.; Barry, S.; Dean, E.; Martin-Mills, J.; Wisinski, K.; Moorthy, G.; Mills, J.; Cruzalegui, F.; Tolaney, S.; Lang, J.; Jose De Miquel Luken, M.; Kunar, R.; Chatta, G.
• Is Part Of: European journal of cancer. Volume 69(2016)supplement 1
• Page Start: S19
• Publication Date: 2016-12
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)32637-5
• Languages: English
• ISSNs: 0959-8049